Results 31 to 40 of about 6,339,547 (295)

Vanishing shortcoming and asymptotic relative efficiency [PDF]

open access: yes, 2000
The shortcoming of a test is the difference between the maximal attainable power and the power of the test under consideration. Vanishing shortcoming, when the number of observations tends to infinity, is therefore an optimality property of a test. Other
Inglot, Tadeusz   +2 more
core   +2 more sources

Power Performance Verification of a Wind Farm Using the Friedman’s Test

open access: yesSensors, 2016
In this paper, a method of verification of the power performance of a wind farm is presented. This method is based on the Friedman’s test, which is a nonparametric statistical inference technique, and it uses the information that is collected by the ...
Wilmar Hernandez   +2 more
doaj   +1 more source

A comparison of power approximations for satterthwaite's test

open access: yesCommunications in Statistics - Simulation and Computation, 1995
When testing equality of means from two independent normal populations, many statisticians prefer heterogeneity tolerant tests. Moser, Stevens, and Watts described the noncentral density and a numerical integration algorithm for computing power. We present simple and accurate approximations for the power of the Satterthwaite test statistic.
Rachael L, Disantostefano   +1 more
openaire   +3 more sources

Power of a randomization test in a single case multiple baseline AB design.

open access: yesPLoS ONE, 2020
A randomization test can be used to statistically test hypotheses in multiple baseline designs to complement the commonly used visual inspection analysis. A crossed factor simulation study was performed to investigate the power of a randomization test in
Samantha Bouwmeester, Joran Jongerling
doaj   +1 more source

Power of A Class of Goodness-of-Fit Tests I [PDF]

open access: yesESAIM: Probability and Statistics, 2009
Summary: Consider testing whether \(F = F_{0}\) for a continuous cdf on \(R = (- \infty, \infty)\) and for a random sample \(X_{1},\dots , X_n\) from \(F\). We derive expansions of the associated asymptotic power based on the Cramér-von Mises, Kolmogorov-Smirnov and Kuiper statistics.
Withers, Christopher S.   +1 more
openaire   +2 more sources

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait   +23 more
wiley   +1 more source

A computational predictor of the anaerobic mechanical power outputs from a clinical exercise stress test.

open access: yesPLoS ONE, 2023
We previously were able to predict the anaerobic mechanical power outputs using features taken from a maximal incremental cardiopulmonary exercise stress test (CPET).
Efrat Leopold   +2 more
doaj   +1 more source

Power gain by pre-testing? [PDF]

open access: yes, 1999
The aim of this paper is to study whether it is possible to gain power by pre-testing, and to give insight in when this occurs, to what extent, and, at which price. A pre-test procedure consists of a preliminary test which tests a particular property of
Albers, W.   +2 more
core   +1 more source

Preferences of Pediatric Patients and Their Caregivers for Chemotherapy‐Induced Nausea and Vomiting Control Endpoints: A Mixed Methods Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Although not always achieved, complete chemotherapy‐induced nausea and vomiting (CINV) control is the conventional goal of CINV prophylaxis. In this two‐center, mixed‐methods study, we sought to understand the preferences of adolescent patients and family caregivers for CINV control endpoints.
Haley Newman   +8 more
wiley   +1 more source

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy